Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

FDA's draft guidance document addresses artificial pancreas system for type 1 diabetes

The U.S. Food and Drug Administration today issued draft guidance that will help advance the development and approval of an artificial pancreas system to treat type 1 diabetes in the United States.

21 Jun 2011

JDRF launches clinical trials network for treatment of type 1 diabetes

Juvenile Diabetes Research Foundation (JDRF) Canada has announced the official launch of its large-scale effort to support clinical trials evaluating new treatments and technologies for type 1 diabetes in Canada.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.

15 Jun 2011

Abbott’s CREON receives FDA approval for infant-specific dose

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines for infant dosing.

14 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin Pharmaceuticals, Inc. today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company from engaging in anticompetitive activity and breaching its diabetes collaboration agreement with Amylin.

10 Jun 2011

Closed-loop artificial pancreas could fight against Type 1 diabetes

Engineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from oil refining and other diverse areas to help create a closed-loop artificial pancreas. The device will automatically monitor blood sugar levels and administer insulin to patients with Type 1 diabetes, and aims to remove much of the guesswork for those living with the chronic disease.

8 Jun 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Amylin Pharmaceuticals, Inc. today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

26 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Diabetes in Control publishes complete list of drugs that affect blood glucose

Any clinician knows that there's a massive amount of new diabetes research and clinical information released daily, which makes keeping pace with best practices almost a full-time job.

20 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

ACE survey: 55% of patient with type 2 diabetes experience hypoglycemia

New survey data released today at the American Association of Clinical Endocrinologists 20th Annual Meeting and Clinical Congress reveal that more than half of people with type 2 diabetes across the country report they have experienced hypoglycemia, or low blood sugar.

15 Apr 2011

Medtronic introduces Enlite Sensor for continuous glucose monitoring

Medtronic, Inc. announces the launch of Enlite Sensor, the newest and most advanced glucose sensor for continuous glucose monitoring, in more than 35 countries outside of the United States.

12 Apr 2011

Refined carbohydrates create an ill and obese population

When it comes to feeding a body well, we've all been told we need proteins, fats and carbohydrates. For years, many of those we trust for health information have told us that the foundation of our diet should primarily consist of carbohydrates, namely, grains, breads and pastas.

8 Apr 2011

New medical guidelines for diabetes care

Today the American Association of Clinical Endocrinologists released new medical guidelines for developing comprehensive care plan for management of diabetes mellitus.

6 Apr 2011

Hypoglycemia News and Research

Further Reading

FDA's draft guidance document addresses artificial pancreas system for type 1 diabetes

JDRF launches clinical trials network for treatment of type 1 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott’s CREON receives FDA approval for infant-specific dose

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Closed-loop artificial pancreas could fight against Type 1 diabetes

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Diabetes in Control publishes complete list of drugs that affect blood glucose

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

ACE survey: 55% of patient with type 2 diabetes experience hypoglycemia

Medtronic introduces Enlite Sensor for continuous glucose monitoring

Refined carbohydrates create an ill and obese population

New medical guidelines for diabetes care

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News